2025-11-15 | Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review PDF Report Presentation Webcast
2025-11-10 | Ascelia Pharma Files New Patent Application for Orviglance PDF Report Presentation Webcast
2025-09-03 | Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration PDF Report Presentation Webcast
2025-08-15 | Ascelia Pharma Updates Timeline for Submission of the Orviglance NDA PDF Report Presentation Webcast
2025-04-08 | Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology PDF Report Presentation Webcast
2025-04-04 | Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference PDF Report Presentation Webcast
Regulatory 2025-03-31 | The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025 PDF Report Presentation Webcast
Regulatory 2025-03-18 | Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025 PDF Report Presentation Webcast
2025-01-27 | Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting PDF Report Presentation Webcast
2024-12-23 | Ascelia Pharma Patent Granted in China for Second Generation Orviglance PDF Report Presentation Webcast
2024-12-17 | Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025 PDF Report Presentation Webcast
2024-12-02 | Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting PDF Report Presentation Webcast
2024-11-06 | Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE PDF Report Presentation Webcast
2024-10-24 | Ascelia Pharma Presents Late-Breaking Abstract on SPARKLE Data at the American Society of Nephrology Kidney Week Congress 2024 PDF Report Presentation Webcast
2024-09-30 | Ascelia Pharma Finalizes Rights Issue with Runway Extended to Late 2025 PDF Report Presentation Webcast
2024-05-07 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
2024-04-18 | Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility PDF Report Presentation Webcast
